Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03373006 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Prostate Cancer
A Phase 2 study, sponsored by HALO Diagnostics.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03373006 is a Phase 2 study that has completed, run by HALO Diagnostics. The registered enrollment target is 20 participants.
The verdict
NCT03373006, a Phase 2 study, has completed, sponsored by HALO Diagnostics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
To investigate the utility of fluciclovine F 18 for evaluation for metastatic disease in men undergoing laser focal therapy of prostate cancer and the impact on inclusion for a focal therapy cohort.
Interventions
- DRUG Axumin PET/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2020-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03373006
The ClinicalTrials.gov registry entry for NCT03373006 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HALO Diagnostics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Axumin PET/CT is the first listed.
NCT03373006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03373006 about?
NCT03373006 is a clinical study titled "A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Prostate Cancer". To investigate the utility of fluciclovine F 18 for evaluation for metastatic disease in men undergoing laser focal therapy of prostate cancer and the impact on inclusion for a focal therapy cohort.
What is the current status of trial NCT03373006?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2018-02-27. Estimated completion is 2020-01-30.
What interventions are being tested in trial NCT03373006?
The interventions under investigation include: Axumin PET/CT (DRUG).
Who is sponsoring clinical trial NCT03373006?
This trial is sponsored by HALO Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.